Literature DB >> 1656853

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

R Wise1, M Logan, M Cooper, J M Andrews.   

Abstract

The pharmacokinetics of tazobactam (500 mg) administered intravenously alone were compared with the pharmacokinetics of tazobactam coadministered with piperacillin (4 g), and the penetration into an inflammatory exudate in six healthy males was studied. Piperacillin influenced the pharmacokinetics of tazobactam. The mean levels of tazobactam in plasma at 4 h were 0.6 microgram/ml when it was given alone and 1.2 micrograms/ml when it was given with piperacillin (P = 0.0003). The mean total clearances of tazobactam were 203.5 and 134.2 ml/min (P = 0.035) when it was given alone and with piperacillin, respectively There were no significant differences in the elimination half lives, areas under the concentration-time curve from 0 h to infinity, or volumes of distribution. Inflammatory exudate penetration was rapid, and the mean maximum levels of tazobactam attained were 6.4 and 11.3 micrograms/ml when it was given alone or with piperacillin, respectively (P less than 0.06). The mean percent penetration of tazobactam and the area under the concentration-time curve from 0 h to infinity in inflammatory exudate were greater when tazobactam was given with piperacillin. The mean 24-h urinary recoveries of tazobactam were 63.7% +/- 7.9% when it was given alone and 56.8% +/- 2.7% when it was given with piperacillin. The explanation for the differences in the pharmacokinetics of tazobactam when it was administered alone compared with those when it was given with piperacillin was unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656853      PMCID: PMC284290          DOI: 10.1128/AAC.35.6.1081

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.

Authors:  J M Diver; D Thornber; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-07       Impact factor: 5.790

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers.

Authors:  A L Barry; L W Ayers; T L Gavan; E H Gerlach; R N Jones
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

4.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

6.  Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.

Authors:  P J De Schepper; T B Tjandramaga; A Mullie; R Verbesselt; A van Hecken; R Verberckmoes; L Verbist
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

7.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

8.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

9.  Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

10.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

View more
  27 in total

1.  Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Authors:  M Kinzig; F Sörgel; B Brismar; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Assessment of biliary excretion of piperacillin-tazobactam in humans.

Authors:  J F Westphal; J M Brogard; F Caro-Sampara; M Adloff; J F Blicklé; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.

Authors:  Shamir N Kalaria; Mathangi Gopalakrishnan; Emily L Heil
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  Piperacillin-tazobactam penetration into human pancreatic juice.

Authors:  Elisa Bertazzoni Minelli; Anna Benini; Luigina Franco; Claudio Bassi; Paolo Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

6.  Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.

Authors:  F Jehl; C Muller-Serieys; V de Larminat; H Monteil; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.

Authors:  Kamalpreet Kaur; Anita Gupta; Amarjeet Sharma; Geeta Walia; Bikramdeep Singh; Kiranpreet Kaur
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 8.  Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Authors:  George G Zhanel; Phillip Chung; Heather Adam; Sheryl Zelenitsky; Andrew Denisuik; Frank Schweizer; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Andrew Walkty; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

9.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.